Bolt Biotherapeutics, Inc. has announced a significant update regarding its stock ownership. Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have disclosed that they now hold a combined 4.82% of the company's common stock. This development highlights ongoing interest in Bolt Biotherapeutics and reflects the competitive landscape of the pharmaceutical preparations sector.
Background
Bolt Biotherapeutics, Inc. operates in the pharmaceutical preparations industry, specifically under the SIC code 2834. The company trades on the Nasdaq under the ticker symbol BOLT. As an emerging growth company and a smaller reporting company, Bolt Biotherapeutics is focused on developing innovative therapies to address unmet medical needs. Recent filings indicate a proactive approach to maintaining transparency with its investors.
What the Filing Says
The recent filing, a Schedule 13G/A, was submitted on November 12, 2026, and indicates that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have beneficially owned 92,925 shares of Bolt Biotherapeutics. The filing states, "This Schedule 13G is being filed by Renaissance Technologies LLC ('RTC') and Renaissance Technologies Holdings Corporation ('RTHC')." This ownership represents 4.82% of the company's total shares.
Impact
The disclosure of this stake may affect investor sentiment regarding Bolt Biotherapeutics, as it indicates confidence from a well-known investment firm. The involvement of Renaissance Technologies could attract further interest from other institutional investors, potentially impacting the company's market dynamics. As the pharmaceutical preparations sector continues to evolve, such changes in ownership can signal shifts in market confidence and investment strategies.
What's Next
Details were not available in the SEC filing regarding future actions or implications stemming from this ownership stake. Investors and analysts will likely monitor Bolt Biotherapeutics for any further developments or filings that may provide additional insights into the company's strategic direction.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





